Molecular Partners AG (SWX:MOLN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
3.215
-0.100 (-3.02%)
Apr 3, 2025, 2:44 PM CET
-12.64%
Market Cap 122.24M
Revenue (ttm) 4.97M
Net Income (ttm) -54.04M
Shares Out 36.87M
EPS (ttm) -1.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 21,089
Average Volume 29,954
Open 3.275
Previous Close 3.315
Day's Range 3.175 - 3.275
52-Week Range 3.105 - 9.500
Beta 0.61
RSI 36.13
Earnings Date Mar 7, 2025

About Molecular Partners AG

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (D... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 159
Stock Exchange SIX Swiss Exchange
Ticker Symbol MOLN
Full Company Profile

Financial Performance

In 2024, Molecular Partners AG's revenue was 4.97 million, a decrease of -29.38% compared to the previous year's 7.04 million. Losses were -54.04 million, -12.81% less than in 2023.

Financial Statements

News

Molecular Partners to hold three poster presentations at AACR 2025

Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212 Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer

8 days ago - GlobeNewsWire

Molecular Partners Publishes Invitation to Annual General Meeting 2025

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-...

8 days ago - GlobeNewsWire

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotec...

27 days ago - GlobeNewsWire

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-b...

4 weeks ago - GlobeNewsWire

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech...

2 months ago - GlobeNewsWire

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., and PARIS, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-...

2 months ago - GlobeNewsWire

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-b...

3 months ago - GlobeNewsWire

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity

4 months ago - GlobeNewsWire

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only

5 months ago - GlobeNewsWire

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data expected...

5 months ago - GlobeNewsWire

Molecular Partners prices $20M offering

5 months ago - Seeking Alpha

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biote...

5 months ago - GlobeNewsWire

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

Dose-dependent efficacy observed with favorable safety profile Attractive tumor to kidney ratios shown in biodistribution studies Picomolar affinity and high specificity for DLL3 as precision attribut...

5 months ago - GlobeNewsWire

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) --  Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biot...

5 months ago - GlobeNewsWire

Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting

Preclinical proof-of-concept data supports CD3 Switch-DARPin platform for T cell engagers with enhanced function in solid tumors Biomarker data on completed phase 1 study of MP0317 (FAP x CD40) shows ...

6 months ago - GlobeNewsWire

Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024

First RDT candidate MP0712 shows low kidney accumulation and high tumor uptake in preclinical models MP0712 treatment leads to strong tumor growth inhibition with a good safety profile in vivo ZURICH-...

6 months ago - GlobeNewsWire

Molecular Partners reports 1H results

7 months ago - Seeking Alpha

Molecular Partners Reports H1 2024 Corporate Highlights and Financials

First Radio-DARPin Therapy (RDT) candidate MP0712 nominated; supporting preclinical package presented at SNMMI; initial clinical data expected in 2025

7 months ago - GlobeNewsWire

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-b...

10 months ago - GlobeNewsWire